{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000069","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.966172+00:00","generated_at":"2026-05-16T17:59:36.576258+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Indivior pays $295M to DOJ, concludes legacy resolution agreement","bullets":["Paid $295M in full to DOJ using cash on hand, resolving 2020 Resolution Agreement.","Resolution Agreement terminated on November 20, 2025.","CEO Joe Ciaffoni says milestone removes significant liability and simplifies capital structure.","Company reaffirms commitment to compliance and transparency."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000069","json":"https://secwatch.observer/filing/0001625297-25-000069.json","markdown":"https://secwatch.observer/filing/0001625297-25-000069.md","text":"https://secwatch.observer/filing/0001625297-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000069/0001625297-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000069/indv-20251120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:59:36.576258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}